Group 1 - The core point of the article is that China Civil Aviation Information Network Co., Ltd. has applied for a patent for a ticket price search configuration method, system, electronic device, and storage medium, which aims to enhance the efficiency and user experience of ticket price searches [1][3] - The patent application was filed on December 2024, with the publication number CN119848324A [1] - The method involves distinguishing between trial calculation requests and user requests, utilizing both database and local cache data to improve real-time access and reduce resource consumption during the ticket price search process [1] Group 2 - China Civil Aviation Information Network Co., Ltd. was established in 2000 and is based in Beijing, primarily engaged in internet and related services [2] - The company has a registered capital of 2,926.209589 million RMB and has invested in 39 enterprises [2] - The company has participated in 2,259 bidding projects and holds 1,787 patent information records, along with 137 trademark information records and 166 administrative licenses [2]

中新社柏林4月19日电维也纳消息：联合国工业发展组织(工发组织)18日在其网站发表文章，就美国滥 施关税对全球贸易、经济增长的消极影响阐明看法。 文章指出，美方滥施关税的做法是错误的，将对世界经济增长和产业发展带来巨大风险，削弱发展中国 家和最不发达国家充分参与全球贸易的潜力，抵消这些国家工业现代化和经济多元化努力。 文章表示，最新估计显示，约有4.5亿人在全球供应链中工作。发达国家保护主义抬头将减少就业岗位 和经济机会，减缓工业化进程，阻碍减贫努力。关税上升所带来的负面影响不仅会波及那些本就脆弱的 国家，也会影响实施关税的国家自身，加剧地缘政治紧张局势和不确定性。 工发组织指出，美国加征关税并非基于事实，也不会取得预期效果。加征关税将推高工业生产成本，降 低经济效率，抵消贸易红利，削弱竞争能力，最终危及全球就业，并且会给经济最脆弱的国家带来最沉 重打击。 工发组织总干事穆勒在文章中表示，各国应致力于建立更加公平和可持续的全球经济体系，而非设置贸 易壁垒。美国退出发展合作、经济合作、拒绝承担共同责任，已经引发危险的连锁反应。包括美国在内 的所有工业化国家应同发展中国家共创互利共赢，构建更加公平、更可持续的全球 ...

近日，巨子生物（02367.HK）旗下护肤品牌可复美被消费者投诉含有违禁成分EGF（表皮生长因子）一事引起热议。此事源于今年4月11日有媒体报道，一 位消费者称2023年8月使用了"可复美重组胶原蛋白修复敷料（G型）"后脸部发硬肿胀，该消费者2024年2月购买同款产品自行送检，样品被检出EGF。4月12 日，可复美官方发布声明称，公司已委托两家专业检测机构分别采用两种检测方法对同批次产品独立检测，均未检出EGF。 南都湾财社记者注意到，此事引发热议后，巨子生物属地市场监管局被质疑对此事是否知晓及核查情况。4月17日，陕西省药品监督管理局对此事发布情况 通报称，该局在2024年3月已收到举报人提供的检验报告，2024年3月、4月该局对陕西巨子生物技术有限公司进行现场检查，未发现企业存在生产过程中添 加EGF的情况，因此于2024年11月5日作出不予立案决定。 陕西省药监局表示，2025年4月，该局再次对巨子生物开展针对性飞行检查，现场未发现企业违规添加"表皮生长因子（EGF）"行为。为进一步防控风险， 该局针对该产品开展了抽样检验，因目前国内尚无医疗器械医用敷料中"表皮生长因子（EGF）"标准化检测方法，该局采 ...

Group 1 - The 2025 Wave Digital Enterprise Innovation Conference was held in Beijing with the theme "AI Towards New, Tides Surge Future," highlighting the rapid iteration of global AI technology as a core driver for enterprise digital transformation [1] - The conference emphasized the importance of leveraging AI to reshape core competitiveness and accelerate the implementation of high-value intelligent application scenarios [1] - Liu Jiyong, General Manager of Inspur Group, stated that AI has evolved from a technical concept to a core force driving new productive forces and restructuring the global competitive landscape [1] Group 2 - Li Yizhong, President of the China Industrial Economic Federation, stressed the need to accelerate the application of AIGC in manufacturing and develop AI large models and specialized models for various processes in production and operations [2] - The conference included various forums and events, such as a technology innovation conference and an ecological partner conference, focusing on topics like intelligent finance, smart human resources, decision intelligence, and intelligent manufacturing [2] - New AI achievements, including Inspur Haiyue Business AI, were announced during the conference [2]

今年注定是个"魔芋大年"，魔芋品类热度提升、市场持续扩容，魔芋零食赛道迎来强劲增长势能。 《2023—2028年中国魔芋行业市场需求与投资咨询报告》显示，2022年我国魔芋市场规模约39.8亿元，2023年同比增长 16.26%。作为魔芋零食赛道开创者，卫龙美味早在2014年便推出魔芋爽，凭借"低热量""高膳食纤维"定位引领行业增长，其蔬 菜制品业务已成为第二增长曲线。 本报讯 （记者李静）4月18日，辣味休闲食品行业龙头卫龙美味全球控股有限公司（以下简称"卫龙美味"）旗下品牌卫龙 魔芋爽官宣青年演员王安宇为品牌代言人，其"清爽少年感"形象与魔芋爽"好吃少负担"特质高度契合，双方推出王安宇同款蓝 色魔芋爽礼盒，精准切入年轻消费圈层。礼盒除经典口味外，还新增"麻酱"风味，以"浓郁麻酱味、口口芝麻香"创新辣感体 验，进一步丰富产品矩阵。 图源：企业供图 卫龙魔芋爽能够取得如今的成就，离不开其持续驱动"产品+营销"双轮创新。从去年魔芋爽的一系列营销动作中就可以看 出，卫龙魔芋爽在对话年轻消费者这件事上向来走在前列，不论是推出"人类猫条"限定包装+周边组合引发社媒广泛讨论，还 是魔芋爽上菜了营销用"湘"味限定风味抓住 ...

经济观察报记者濮振宇 4月14日，香港交易所的铜锣声为江苏正力新能电池技术股份有限公司(下称"正力新能")(03677.HK)敲 响。截至4月17日收盘，正力新能股价为8.4港元，总市值达到210.71亿港元。 作为一家成立仅五年多的动力电池企业，正力新能在2024年以51.3亿元营收和9101万元净利润的成绩 单，完成了从"跌入深渊"到"绝地上市"的惊险一跃。这一切的幕后操盘者，是"玻璃大王"曹德旺的胞妹 ——曹芳。 实现港股上市，并不意味着正力新能摆脱了生存压力。随着动力电池行业洗牌加剧，在宁德时代 （300750）和比亚迪（002594）两大巨头制霸市场的背景下，正力新能这一"幸存者"究竟能走多远，仍 然有待观察。 早年被威马拖累，靠零跑重新回血 2019年，从福耀玻璃（600660）离职五年的曹芳，带着在汽车行业摸爬滚打二十年的经验，与福耀玻璃 原高管陈继程共同创立正力新能，瞄准新能源汽车浪潮下的动力电池赛道。 在正力新能成立之前，曹芳旗下的新中源创投与丰田合资创立了新中源丰田，新中源丰田为丰田的混 动、插混车型提供电池系统。不仅如此，曹芳还成立了正力投资，并投资过三家公司，分别是正力新能 源、正力芯 ...

Group 1 - The core viewpoint emphasizes the importance of both large and small models in the digital transformation of industrial enterprises, highlighting the integration of generative AI in five key areas: innovative design, industrial enhancement, quality reinforcement, service extension, and market expansion [1] - The conference, themed "AI Towards New, Tides Surge Future," gathered over a thousand participants, including academicians, industry leaders, and representatives from enterprises and authoritative institutions, to discuss AI models, commercial AI, industrial software, and global market expansion [1] - The general manager of Inspur Group stated that AI has evolved from a technical concept to a core driving force for enterprise development, reshaping global competitive dynamics and accelerating comprehensive transformations across various industries [1] Group 2 - The rapid adoption of AI, particularly large models, has created a widespread and urgent demand for digital transformation among enterprises [2] - Key strategies for accelerating the implementation of intelligent systems include recognizing AI's long-term value, understanding the current maturity stage of enterprises, planning AI application scenarios, and selecting suitable partners [2] - Inspur Digital Enterprises has outlined a four-step transition for digital transformation, which includes "Composite AI," "Data Foundation," "Tool Chain Supplement," and "Software Reconstruction," under its "AI First Strategy" [2] Group 3 - Inspur officially launched the Haiyue Commercial AI and Haiyue Model 3.0, targeting business pain points in enterprise management and production operations, aiming to bridge the "last mile" of intelligent implementation [3] - The conference also introduced a "Global Ecological Strategy" to assist Chinese enterprises in achieving global ecological collaborative value through technological symbiosis, market expansion, and standard co-construction [3] - Various specialized forums were held during the conference, covering topics such as intelligent finance, smart human resources, decision intelligence, and intelligent manufacturing, showcasing Inspur's product capabilities and industry practices [3]

Core Insights - A total of 10 first-class innovative drugs have received clinical trial approval in China from April 14 to April 19, covering various types including small molecules, antibody-drug conjugates (ADC), gene therapy, and cell therapy, targeting conditions such as advanced solid tumors, type 1 diabetes, spinal cord injury, Duchenne muscular dystrophy (DMD), and paroxysmal nocturnal hemoglobinuria [1] Group 1: Company-Specific Developments - Hansoh Pharmaceutical's HS-10529, a KRAS G12D small molecule inhibitor, has been approved for clinical trials to treat advanced solid tumors with KRAS G12D mutations, showing good preclinical efficacy and safety [2] - Kanghong Pharmaceutical's KH815, a TROP2-targeted dual-payload ADC, has received clinical approval for treating advanced solid tumors, demonstrating potential to overcome drug resistance [3] - Innovent Biologics' IBI3020, a CEACAM5-targeted dual-payload ADC, has been approved for clinical trials aimed at treating unresectable, locally advanced, or metastatic solid tumors [4] - Xinneng Pharmaceutical's BBM-D101, an AAV gene therapy drug, has been approved for clinical trials to treat Duchenne muscular dystrophy (DMD), aiming for long-term efficacy with a single administration [5] - Zhixin Haosheng's E-islet 01, a universal allogeneic islet regeneration product, has received clinical approval for treating type 1 diabetes, utilizing advanced cell reprogramming techniques [6] - Shizhe Biotechnology's XS228, an iPSC-derived neural precursor cell injection, has been approved for clinical trials to treat subacute spinal cord injury (SCI) [7] - Baili Pharmaceutical's BL-M09D1, an ADC drug, has been approved for treating locally advanced or metastatic solid tumors, sharing technology with another ADC [8] - Renfu Innovation's HWS116, a biological product, has received clinical approval for treating advanced solid tumors, although specific mechanisms are not yet disclosed [9]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：601666 股票简称：平煤股份 编号：2025-033 平顶山天安煤业股份有限公司 关于控股股东股份质押的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一、控股股东股份质押的基本情况 1.股份质押基本情况 重要内容提示: ●平顶山天安煤业股份有限公司（以下简称"公司"）控股股东中国平煤神马控股集团有限公司（以下简 称"集团"或"中国平煤神马集团"）持有本公司股份1,100,034,147股，占公司总股本的44.44%，累计质押 公司股份640,000,000股，占公司总股本的25.84%。 ●中国平煤神马控股集团及其一致行动人持有本公司股份1,151,273,546股，占公司总股本的46.51%，累 计质押公司股份640,000,000股，占其所持股份数量的55.59%。 2018年，集团与招商证券资产管理公司、深圳市前海建合投资管理有限公司及河南平煤神马投资管理公 司共同发起设立河南平煤神马集团产业转型发展基金（有限合伙）。2018年3月22日， ...

海报新闻记者 孙佃潇 报道 近日，珍酒李渡集团有限公司（以下简称"珍酒李渡"）2024年度业绩公告显示，该公司全年实现营业收 入70.67亿元，同比增长0.5%；经调整净利润16.76亿元，同比增长3.3%。不过，海报新闻记者注意到， 其旗舰品牌珍酒收入有所下滑。 4月18日，海报新闻记者针对相关情况致电了贵州珍酒方面，其工作人员称，公司业务、产品业绩等相 关信息均以官方通告为准。 | 财務编要 | | | | | --- | --- | --- | --- | | 下表粮列截至2024年12月31日止年度我們的關鍵財務教婆 · 連同截至2023年12 月31日止年度的比較數字及變動(以自分比表示)。 | | | | | | 鞋至12月31日止年度 | | | | | 2024年 | 2023 年 | 學動 | | | (人民幣于元) | (人民爵于元) | (8) | | 收入 | 7,066,784 | 7.030.467 | :0.5 | | 毛利 | 4.143.040 | 4.079.948 | 1.5 | | 年内本公司幢益股東感佔利润 | 1,323,622 | 2.327.083 | (43. ...